Research Analysts Offer Predictions for MAZE FY2030 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Research analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Maze Therapeutics in a note issued to investors on Monday, January 26th. HC Wainwright analyst A. Ghosh forecasts that the company will post earnings per share of $0.60 for the year. HC Wainwright currently has a “Buy” rating on the stock.

Several other research analysts have also issued reports on MAZE. Wedbush upped their target price on shares of Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Wells Fargo & Company began coverage on Maze Therapeutics in a report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective on the stock. Finally, Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average target price of $44.50.

Maze Therapeutics Price Performance

MAZE stock opened at $43.36 on Wednesday. The firm has a 50 day simple moving average of $40.52 and a two-hundred day simple moving average of $28.67. The stock has a market cap of $2.09 billion and a PE ratio of -2.07. Maze Therapeutics has a one year low of $6.71 and a one year high of $47.36.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Institutional Investors Weigh In On Maze Therapeutics

Several institutional investors have recently added to or reduced their stakes in MAZE. Vanguard Group Inc. increased its position in shares of Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after acquiring an additional 915,342 shares during the period. Marshall Wace LLP grew its stake in shares of Maze Therapeutics by 3,868.5% in the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after purchasing an additional 758,104 shares during the last quarter. ArrowMark Colorado Holdings LLC purchased a new position in Maze Therapeutics during the 3rd quarter valued at about $14,135,000. Frazier Life Sciences Management L.P. increased its holdings in Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after purchasing an additional 438,274 shares during the period. Finally, Balyasny Asset Management L.P. bought a new position in Maze Therapeutics during the 3rd quarter valued at approximately $11,246,000.

Insider Activity at Maze Therapeutics

In related news, SVP Amy Bachrodt sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $45.52, for a total transaction of $227,600.00. Following the transaction, the senior vice president directly owned 12,965 shares in the company, valued at $590,166.80. This trade represents a 27.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Atul Dandekar sold 72,400 shares of Maze Therapeutics stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $2,936,544.00. Following the completion of the transaction, the insider directly owned 10,503 shares in the company, valued at $426,001.68. This trade represents a 87.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 172,500 shares of company stock worth $7,002,267 in the last ninety days.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.